Olga V Demler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8786906/publications.pdf

Version: 2024-02-01

43 papers 43,673 citations

26 h-index

218677

265206 42 g-index

46 all docs

46 docs citations

46 times ranked

39261 citing authors

#	Article	IF	CITATIONS
1	Quantitative Comparison of Statistical Methods for Analyzing Human Metabolomics Data. Metabolites, 2022, 12, 519.	2.9	7
2	Relationship of DNA methylation and cognitive and neuropsychiatric symptoms among older adults. American Journal of Geriatric Psychiatry, 2021, 29, S49-S50.	1.2	O
3	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiology, 2021, 6, 437.	6.1	82
4	One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL). Metabolites, 2020, 10, 431.	2.9	13
5	Antiâ€Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016507.	3.7	21
6	Metabolomic Effects of Hormone Therapy and Associations With Coronary Heart Disease Among Postmenopausal Women. Circulation Genomic and Precision Medicine, 2020, 13, e002977.	3 . 6	4
7	Using Administrative Data to Predict Suicide After Psychiatric Hospitalization in the Veterans Health Administration System. Frontiers in Psychiatry, 2020, 11, 390.	2.6	33
8	Quantum approximate Bayesian computation for NMR model inference. Nature Machine Intelligence, 2020, 2, 396-402.	16.0	12
9	Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL. Journal of Clinical Lipidology, 2020, 14, 241-251.	1.5	17
10	Pleiotropy-Based Decomposition of Genetic Risk Scores: Association and Interaction Analysis for Type 2 Diabetes and CAD. American Journal of Human Genetics, 2020, 106, 646-658.	6.2	17
11	Association of the Mediterranean Diet With Onset of Diabetes in the Women's Health Study. JAMA Network Open, 2020, 3, e2025466.	5 . 9	28
12	Statistical Workflow for Feature Selection in Human Metabolomics Data. Metabolites, 2019, 9, 143.	2.9	55
13	A Single Visualization Technique for Displaying Multiple Metabolite–Phenotype Associations. Metabolites, 2019, 9, 128.	2.9	15
14	Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment. Contemporary Clinical Trials, 2019, 87, 105854.	1.8	24
15	Measures for evaluation of prognostic improvement under multivariate normality for nested and nonnested models. Statistics in Medicine, 2019, 38, 3817-3831.	1.6	6
16	Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet. JAMA Network Open, 2018, 1, e185708.	5.9	65
17	Reclassification calibration test for censored survival data: performance and comparison to goodness-of-fit criteria. Diagnostic and Prognostic Research, 2018, 2, .	1.8	5
18	Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. Circulation Genomic and Precision Medicine, 2018, 11, e002157.	3.6	145

#	Article	IF	Citations
19	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. Circulation, 2017, 135, 2494-2504.	1.6	180
20	Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20Âyears: The Women's Health Study. Journal of Clinical Lipidology, 2017, 11, 1257-1267.e2.	1.5	40
21	Clinical risk reclassification at 10Âyears. Statistics in Medicine, 2017, 36, 4498-4502.	1.6	10
22	Asymptotic distribution of â^†AUC, NRIs, and IDI based on theory of Uâ€statistics. Statistics in Medicine, 2017, 36, 3334-3360.	1.6	20
23	Tests of calibration and goodnessâ€ofâ€fit in the survival setting. Statistics in Medicine, 2015, 34, 1659-1680.	1.6	216
24	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. Clinical Chemistry, 2015, 61, 1156-1163.	3.2	53
25	Impact of correlation on predictive ability of biomarkers. Statistics in Medicine, 2013, 32, 4196-4210.	1.6	17
26	Pencina et al. Respond to "The Incremental Value of New Markers" and "Clinically Relevant Measures? A Note of Caution". American Journal of Epidemiology, 2012, 176, 492-494.	3.4	5
27	Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. Statistics in Medicine, 2012, 31, 101-113.	1.6	250
28	Misuse of DeLong test to compare AUCs for nested models. Statistics in Medicine, 2012, 31, 2577-2587.	1.6	192
29	Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normality. Statistics in Medicine, 2011, 30, 1410-1418.	1.6	29
30	The Prevalence and Correlates of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication. American Journal of Psychiatry, 2006, 163, 716-723.	7.2	2,891
31	The Prevalence and Correlates of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication. American Journal of Psychiatry, 2006, 163, 716.	7.2	1,544
32	Changing Profiles of Service Sectors Used for Mental Health Care in the United States. American Journal of Psychiatry, 2006, 163, 1187.	7.2	218
33	Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 2005, 62, 593.	12.3	15,111
34	Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 2005, 62, 617.	12.3	9,446
35	The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychological Medicine, 2005, 35, 245-256.	4.5	2,316
36	The Prevalence and Correlates of Nonaffective Psychosis in the National Comorbidity Survey Replication (NCS-R). Biological Psychiatry, 2005, 58, 668-676.	1.3	336

#	Article	IF	CITATION
37	Prevalence and Treatment of Mental Disorders, 1990 to 2003. New England Journal of Medicine, 2005, 352, 2515-2523.	27.0	1,592
38	The US National Comorbidity Survey Replication (NCS-R): design and field procedures. International Journal of Methods in Psychiatric Research, 2004, 13, 69-92.	2.1	757
39	Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMH-CIDI). International Journal of Methods in Psychiatric Research, 2004, 13, 122-139.	2.1	425
40	The Epidemiology of Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2003, 289, 3095.	7.4	6,692
41	Comorbid Mental Disorders Account for the Role Impairment of Commonly Occurring Chronic Physical Disorders: Results From the National Comorbidity Survey. Journal of Occupational and Environmental Medicine, 2003, 45, 1257-1266.	1.7	271
42	Adequacy of Treatment for Serious Mental Illness in the United States. American Journal of Public Health, 2002, 92, 92-98.	2.7	435
43	The effects of co-morbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys. Psychological Medicine, 2002, 32, 1213-1225.	4.5	63